Parabilis Medicines, a clinical-stage biotechnology company focused on developing peptide-based cancer therapies, has appointed Helen Ho as Chief Business and Strategy Officer and promoted Thomas Kotarakos to Chief Financial Officer. Dr. Helen Ho, Chief Business and Strategy Officer Ho joins Parabilis with more than 20 years of experience in biopharmaceutical strategy and corporate development. She most recently served as chief business officer at Blueprint Medicines, where she helped lead...